Novartis considers how to price its blockbuster-to-be; Egalet's oxycodone proves tough to abuse;

@FierceBiotech: Biotech billionaire Soon-Shiong plots a second IPO for NantHealth. News | Follow @FierceBiotech

@JohnCFierce: Op-Ed: Is Celgene killing the traditional biotech partnering formula? More | Follow @JohnCFierce

@DamianFierce: $CELG is basically a microlending platform for oncology biotechs. More | Follow @DamianFierce

> Novartis' ($NVS) heart treatment LCZ696 is widely expected to win FDA approval this year, and analysts expect it to quickly become a top seller. And the company, without disclosing how much the drug might cost, is talking up the idea of performance-based pricing, a shakeup to the traditional model. News

> Egalet's ($EGLT) take on oxycodone succeeded in a trial to determine its abuse deterrence, taking 5 times as much effort to break its tablets as required for OxyContin. More

> Alexandria Real Estate's ($ARE) planned $500 million project in Cambridge, MA's Kendall Square will bring in more than 400,000 square feet of rentable space, changing the climate in an area that has seen vacancy rates plummet in recent years. News

Medical Device News

@FierceMedDev: UPDATED: Microchips Biotech partners with Teva on wireless drug delivery, announces new CEO, raises $18M in financing. FierceDrugDelivery story | Follow @FierceMedDev

@VarunSaxena2: FDA warns that transdermal patch for ADHD can lead to permanent skin discoloration. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: AdverseEvents flags TB reports, blood-disorder cases linked to RA drugs. FiercePharma report | Follow @EmilyWFierce

> Investors punish micro-cap EnteroMedics as it raises $35M to market recently approved obesity device. Report

> Startup gets CE mark for novel blood-draw tech after FDA clearance, Series A earlier this year. Story

> DOJ calls off investigation of Abiomed's Impella marketing. Article

Pharma News

@FiercePharma: ICYMI yesterday: Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say. Report | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: France's TxCell closes its plant at ANSM urging to avoid contamination. Article | Follow @EricPFierce

@CarlyHFierce: Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say. More | Follow @CarlyHFierce

> Novartis tests performance pricing for much-anticipated Entresto launch. Report

> Allergan to close plant in Iceland, lay off 300. Item

> Boehringer charges ahead with sale of U.S. generics biz with bids from Hikma, Mallinckrodt. Article

Drug Delivery News

> Cynapsus' sublingual Parkinson's med for levodopa nonresponders progresses to PhIII. Report

> Langer Lab company gets $5M in funding for drug-delivery device. Item

> OptiNose heralds late-stage clinical success for nasal anti-inflammatory. More

> Alnylam's hemophilia candidate reduces levels of anticoagulant in PhI study. Article

> FDA warns that transdermal patch for ADHD can lead to permanent skin discoloration. Story

Pharma Manufacturing News

> Capsugel completes $25M spray-dried expansion. Item

> India's Dr. Reddy's recalls 10 lots of two drugs that failed specifications. More

> Some Indian drugmakers see M&A preferable to investing in plant upgrades. Article

> Canada's Ropack buying Forest operations on Long Island. Story

> GSK doubles down on Singapore continuous processing plant. Report

Pharma Asia News

> Blurred lines in Japan's vision for healthcare in next two decades. Report

> Out with the old, reimburse the new: Merck's Frazier wades into Australia drug debate. More

> Troubled India's Wockhardt sees third U.S. drug recall in as many months. Report

> No artful tax dodging here, drug firms tell Australia transfer-price inquiry. Story

> Taiwan's PharmaEngine racks up good news on MM-398. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.